Gastroenterology News

A cell-free DNA blood-based test detected colorectal cancer with a sensitivity of 83% and a specificity of 90% for advanced neoplasia in an average-risk population, according to new data published in The New England Journal of Medicine.

GLP-1 receptor agonists come with known adverse events — some common and some rare — but recent reports by the public of alopecia and suicidal ideation have the FDA investigating.

Over the past 10 years, the Blue Lights Campaign has illuminated in blue more than 30 iconic landmarks in Philadelphia and beyond to promote the importance of screening during Colorectal Cancer Awareness Month.

Madrigal Pharmaceutical’s Rezdiffra received accelerated FDA approval for the treatment of patients with metabolic dysfunction-associated steatohepatitis with moderate-to-advanced fibrosis, according to a company release.

Changes in intestinal microbiota could play a part in the development of fibromyalgia, most feasibly along the gut-brain axis, according to a systematic review published in the International Journal of Rheumatic Diseases.

The FDA has approved Mirum Pharmaceuticals’ Livmarli oral solution for treatment of cholestatic pruritus in patients aged 5 years and older with progressive familial intrahepatic cholestasis, according to a company release.

Adults with obesity who underwent bariatric surgery had improvements in multiple cardiometabolic measures after surgery, according to findings published in the Journal of the Endocrine Society.

In this Healio video, Folasade P. May, MD, PhD, MPhil, emphasizes the importance of educating patients about colorectal cancer risk and screening all individuals at the “right age and at the right interval.”

Early treatment with infliximab plus an immunomodulator resulted in more frequent steroid-free and surgery-free remission at 1 year compared with conventional therapy among patients with newly diagnosed Crohn’s disease, researchers reported.

As we discussed in our overview of the private equity, or PE, physician practice model, the buyer in an acquisition is often a PE-sponsored management services organization that purchases the nonclinical aspects of the practice’s business.